46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Klebsiella pneumoniae Carbapenemase-producing Enterobacteria in Hospital, Singapore

      letter

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor: During the past decade, enterobacteria that produce Klebsiella pneumoniae carbapenemase (KPC) have become established in the United States and countries in South America and Europe ( 1 ). In Asia, KPC was reported in the People’s Republic of China in 2007 ( 2 ) and subsequently in South Korea ( 3 ) and Taiwan ( 4 ). Public health agencies emphasize screening and strict contact precautions to control multidrug resistant Enterobacteriaceae ( 5 ). Routine testing for mechanisms of resistance facilitates detection of emerging carbapenem-resistant Enterobacteriaceae. In Singapore's 1,000-bed National University Hospital during November 2010–January 2011, we identified New Delhi metallo-β-lactamase 1–producing Enterobacteriaceae in 2 clinical specimens but none that produced KPC (I. Venkatachalam et al., unpub. data). We conducted a laboratory screening study to determine the prevalence and nature of carbapenem-resistant Enterobacteriacea in April 2011. Ethics committee approval was waived for this study. Testing of rectal swab samples is part of an established hospitalwide program for vancomycin-resistant enterococci screening. Using a scoring system to identify patients at high risk for vancomycin-resistant enterococci ( 6 ), we found that ≈2.5 specimens per 100 admissions were attained each month. During our study, we also tested these samples for carbapenemase-producing Enterobacteriaceae. During April–June 2011, we incubated specimens for 24 h in 10 mL tryptic soy broth containing 1 mg/L imipenem, then streaked 100 µL of the broth onto CHROMagar KPC (CHROMagar, Paris, France). Colonies detected after 24 h incubation at 35°C were identified by using MALDI-TOF MS with a Microflex LT instrument (Bruker Daltonik GmbH, Leipzig, Germany). Imipenem and meropenem MICs for Enterobacteriacaeae were confirmed by using Etests (bioMérieux, Marcy l'Etoile, France). Isolates with MIC >2 µg/mL underwent analysis with /Metallo-β-Lactamase Confirmative Identification Pack (Rosco Diagnostica, Taastrup, Denmark) and Etest MBL (bioMérieux) for metallo-β-lactamase production. Isolates suspected to be producers were genotypically confirmed by PCR. Of the 201 nonduplicate samples processed, 79 microorganisms exhibited imipenem resistance and were isolated on CHROMagar KPC (Table). Among Enterobacteriaceae, carbapenem MIC >2 μg/mL was present in 1 E. aerogenes, 2 E. cloacae, and 4 K. pneumoniae isolates. One isolate (K. pneumoniae) had a positive combined disc test result with a pattern suggestive of serine carbapenemase production. Table Bacteria isolated on CHROMagar in screening for carbapenemase-producing Enterobacteriaceae, Singapore, 2011* Organism No. isolated Enterobacteriaceae Klebsiella pneumoniae 11 Enterobacter cloacae 3 Enterobacter aerogenes 2 Proteus mirabilis 2 Escherichia coli 1 Serratia marcescens 1 Non-Enterobacteriaceae: gram-negative nonfermenters Pseudomonas aeruginosa 20 Acinetobacter baumannii 17 Stenotrophomonas maltophilia 13 Elizabethkingia meningoseptica 3 Wautersiella falsenii 1 Enterococci Enterococcus gallinarum 4 Enterococcus faecalis 1 *CHROMagar, Paris, France. We analyzed genomic DNA (DNeasy Blood and Tissue Kit, QIAGEN, Hilden, Germany) from this isolate by using PCR for transmissible carbapenem resistance markers: metallo-β-lactamases (VIM, IMP, and KHM-1), serine carbapenemases (KPC, GES1–5 and 7), and OXA-48. bla KPC-specific primers (forward primer 5′-CGTTGACGCCCAATCC-3′; reverse primer 5′-ACCGCTGGCAGCTGG-3′) generated a 390-bp amplicon. Full gene sequencing of bla KPC (forward primer 5′-ATGTCACTGTATCGCCGTCT-3′; reverse primer 5′-CCTAAATGTGACAGTGGTTGG) revealed 100% homology to bla KPC-2 (GenBank accession no. FJ628167.2). Further analysis showed that the isolate carried extended-spectrum β-lactamase (bla TEM-1, bla SHV-11, bla CTX-M-15), plasmid-located AmpC (bla DHA-1), and 16S rRNA methylase armA genes but was negative for bla CMY, bla OXA, bla GES, metallo-β-lactamases, and plasmid-mediated quinolone (qnr) genes. Multilocus sequence typing conducted at Institut Pasteur (Paris, France), identified this isolate as sequence type 11. It was susceptible only to colistin and tigecycline. Sequence type 11, a single-locus variant of the internationally dominant sequence type 258 clone ( 7 ), is present in 64.2% of KPC-producing K. pneumoniae in China ( 8 ). In South Korea, sequence type 11 is the most common clone of extended-spectrum β-lactamase–producing K. pneumoniae isolates ( 3 ). The KPC-producing K. pneumoniae originated from a woman in the local community, 89 years of age, who had severe ischemic cardiomyopathy and atrial fibrillation. She was discharged home after a 3-day hospitalization for treatment of stroke in January 2011. During May 2011, she was readmitted after a severe stroke. During week 4, she was transferred to a subacute care hospital but readmitted within 24 hours with a lower respiratory tract infection. A rectal swab sample was collected for routine screening for vancomycin-resistant enterococci. We empirically prescribed a 10-day course of piperacillin-tazobactam. On day 10 of treatment, KPC-producing K. pneumoniae was isolated from the rectal specimen. The patient responded to treatment and was discharged to a long-term care facility. This case demonstrates concerns about a KPC of local community origin because no other KPC-producing Enterobacteriaceae were isolated during this inpatient surveillance and the patient had neither received antimicrobial drugs nor traveled in the 6 months before her May admission ( 7 ). However, she was admitted 3 weeks before sampling; an unidentified hospital source remains a possibility. Of added concern is the potential for dissemination within the facility to which she was discharged. Resistance to third-generation cephalosporins was reported for 20% of Escherichia coli, 32.3% of K. pneumoniae, 46.2% of Acinetobacter spp., and 7.5% of Pseudomonas aeruginosa clinical isolates at 4 major Singapore hospitals during January 2006–December 2008 ( 9 ). Authors reported positive correlation between meropenem administration and carbapenem resistance development in Acinetobacter spp. blood isolates. When the resistance mechanism to an antimicrobial drug is embedded in highly mobile elements like plasmids, widespread dissemination is possible. Although acute care hospitals are conducive to development of antimicrobial drug resistance, long-term care facilities facilitate spread of these organisms ( 10 ). Infection control interventions including routine screening for mechanisms of resistance and responsible use of antimicrobial drugs are increasingly critical in hospitals and long-term care facilities; a response plan coordinated between these facilities is needed.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.

          From early this decade, Enterobacteriaceae that produce Klebsiella pneumoniae carbapenemases (KPC) were reported in the USA and subsequently worldwide. These KPC-producing bacteria are predominantly involved in nosocomial and systemic infections; although they are mostly Enterobacteriaceae, they can also be, rarely, Pseudomonas aeruginosa isolates. KPC beta lactamases (KPC-1 to KPC-7) confer decreased susceptibility or resistance to virtually all beta lactams. Carbapenems (imipenem, meropenem, and ertapenem) may thus become inefficient for treating enterobacterial infections with KPC-producing bacteria, which are, in addition, resistant to many other non-beta-lactam molecules, leaving few available therapeutic options. Detection of KPC-producing bacteria may be difficult based on routine antibiotic susceptibility testing. It is therefore crucial to implement efficient infection control measures to limit the spread of these pathogens.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China.

            Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae has spread rapidly in China. In this study, we aimed to investigate the molecular epidemiology of KPC-producing K. pneumoniae isolates in China. Ninety-five carbapenem-resistant K. pneumoniae isolates from 13 hospitals in nine cities covering five provinces in China were analysed. Antibiotic susceptibility was determined by the Etest. Multilocus sequence typing (MLST) and PFGE were used for epidemiological analysis. The genetic structure around bla(KPC) and the encoding genes of extended-spectrum β-lactamases and plasmid-mediated AmpC enzymes were detected by PCR and sequencing. Plasmids were analysed by transformation, restriction and Southern blot. All isolates harboured the bla(KPC-2) gene. Seven sequence types (STs) were obtained. The dominant clone was ST11 (61/95), which was identified in isolates from Zhejiang province (four hospitals in Hangzhou and one hospital in Ningbo), Jiangsu province (one hospital in Nanjing) and Anhui province (one hospital in Hefei). Isolates with ST11 showed >80% similarity in PFGE patterns. Plasmids from 14 selected transformants, their original isolates representing different STs and/or regions, had a diversity of HindIII restriction maps. The dominant clone of KPC-producing K. pneumoniae in China is ST11, which is closely related to ST258, which has been reported worldwide.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities.

              (2009)
              Infection with carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae is emerging as an important challenge in health-care settings. Currently, carbapenem-resistant Klebsiella pneumoniae (CRKP) is the species of CRE most commonly encountered in the United States. CRKP is resistant to almost all available antimicrobial agents, and infections with CRKP have been associated with high rates of morbidity and mortality, particularly among persons with prolonged hospitalization and those who are critically ill and exposed to invasive devices (e.g., ventilators or central venous catheters). This report provides updated recommendations from CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC) for the control of CRE or carbapenemase-producing Enterobacteriaceae in acute care (inpatient) facilities. For all acute care facilities, CDC and HICPAC recommend an aggressive infection control strategy, including managing all patients with CRE using contact precautions and implementing Clinical and Laboratory Standards Institute (CLSI) guidelines for detection of carbapenemase production. In areas where CRE are not endemic, acute care facilities should 1) review microbiology records for the preceding 6-12 months to determine whether CRE have been recovered at the facility, 2) if the review finds previously unrecognized CRE, perform a point prevalence culture survey in high-risk units to look for other cases of CRE, and 3) perform active surveillance cultures of patients with epidemiologic links to persons from whom CRE have been recovered. In areas where CRE are endemic, an increased likelihood exists for imporation of CRE, and facilities should consider additional strategies to reduce rates of CRE. Acute care facilities should review these recommendations and implement appropriate strategies to limit the spread of these pathogens.
                Bookmark

                Author and article information

                Journal
                Emerg Infect Dis
                Emerging Infect. Dis
                EID
                Emerging Infectious Diseases
                Centers for Disease Control and Prevention
                1080-6040
                1080-6059
                August 2012
                : 18
                : 8
                : 1381-1383
                Affiliations
                [1]National University Hospital, Singapore
                Author notes
                Address for correspondence: Indumathi Venkatachalam, National University Hospital–Infectious Diseases, 5 Lower Kent Ridge Rd, Singapore City 119074, Singapore; email: indumathi_venkatachalam@ 123456nuhs.edu.sg
                Article
                11-0893
                10.3201/eid1808.110893
                3414009
                22840461
                ed01a2f5-61cb-4905-8a64-3b4c514180ce
                History
                Categories
                Letters to the Editor
                Letter

                Infectious disease & Microbiology
                jureen r,lin rtp. klebsiella pneumoniae carbapenamase-producing enterobacteria in hospital,balm mnd,suggested citation for this article: venkatachalam i,bacteria,2011 [letter]. emerg infect dis [serial on the internet]. 2012 aug [date cited]. http://dx.doi.org/10.3201/eid1808.110893,kpc-producing,teo j,klebsiella pneumoniae carbapenemase,vancomycin-resistant enterococci,fisher da,antimicrobial-resistant bacteria,singapore,enterobacteriaceae

                Comments

                Comment on this article